Clear Cell Renal Cell Carcinoma 2021–2022

Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Format: Online
Jezik:engleski
Izdano: MDPI - Multidisciplinary Digital Publishing Institute 2022
Teme:
Online pristup:ONIX_20221117_9783036555188_45
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
_version_ 1869527556038852608
collection Directory of Open Access Books
description Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this tumor make it an exciting meeting point for translational collaboration between clinicians and basic researchers. Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. This tumor is also a good example to investigate the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. A deeper identification of the varied internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizers, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm. Clear cell renal cell carcinoma is also a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway.
format Online
id doab-20.500.12854ir-93788
institution Directory of Open Access Books
language eng
publishDate 2022
publishDateRange 2022
publishDateSort 2022
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-937882024-03-31T13:10:36Z Clear Cell Renal Cell Carcinoma 2021–2022 Manini, Claudia López, José I. clear cell renal cell carcinoma prognosis plasma PD-1 PD-L1 renal cell carcinoma immune checkpoint inhibitors immune related adverse events (irAEs) thyroid cutaneous biomarker DNA methylation epigenetics kidney hypoxia tumor microenvironment SCD-1 oleic acid renal cancer sunitinib resistance miRNA transcriptome pathway analysis nivolumab tissue slice culture PD1 T-cells metastatic clear cell renal cell carcinoma first-line treatment immunotherapy tyrosine kinase inhibitors combinations single-cell RNA sequencing immune landscape cancer immunotherapy intra-tumoral heterogeneity inter-tumoral heterogeneity inter-metastatic heterogeneity renal cell cancer treatment resistance angiogenesis adjuvant therapy prediction model prognostic factor clear cell kidney cancer radiogenomics radiomics machine learning gene expression cystic tumor imaging magnetic resonance surgery ddPCR circulating miRNA diagnosis malignancy histomorphological features PBRM1 immunohistochemistry architectural patterns endothelial cells translational immune checkpoint inhibitor responsiveness molecular features multisite tumor sampling intratumor heterogeneity clear-cell renal cell carcinoma disease progression prognostic factors biomarkers RNA sequencing n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this tumor make it an exciting meeting point for translational collaboration between clinicians and basic researchers. Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. This tumor is also a good example to investigate the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. A deeper identification of the varied internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizers, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm. Clear cell renal cell carcinoma is also a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway. 2022-11-17T16:24:41Z 2022-11-17T16:24:41Z 2022 book ONIX_20221117_9783036555188_45 9783036555188 9783036555171 https://directory.doabooks.org/handle/20.500.12854/93788 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/6216 https://mdpi.com/books/pdfview/book/6216 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-5518-8 10.3390/books978-3-0365-5518-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036555188 9783036555171 342 Basel open access
spellingShingle clear cell renal cell carcinoma
prognosis
plasma
PD-1
PD-L1
renal cell carcinoma
immune checkpoint inhibitors
immune related adverse events (irAEs)
thyroid
cutaneous
biomarker
DNA methylation
epigenetics
kidney
hypoxia
tumor microenvironment
SCD-1
oleic acid
renal cancer
sunitinib
resistance
miRNA
transcriptome
pathway analysis
nivolumab
tissue slice culture
PD1
T-cells
metastatic clear cell renal cell carcinoma
first-line treatment
immunotherapy
tyrosine kinase inhibitors
combinations
single-cell RNA sequencing
immune landscape
cancer immunotherapy
intra-tumoral heterogeneity
inter-tumoral heterogeneity
inter-metastatic heterogeneity
renal cell cancer
treatment resistance
angiogenesis
adjuvant therapy
prediction model
prognostic factor
clear cell kidney cancer
radiogenomics
radiomics
machine learning
gene expression
cystic tumor
imaging
magnetic resonance
surgery
ddPCR
circulating miRNA
diagnosis
malignancy
histomorphological features
PBRM1
immunohistochemistry
architectural patterns
endothelial cells
translational
immune checkpoint inhibitor
responsiveness
molecular features
multisite tumor sampling
intratumor heterogeneity
clear-cell renal cell carcinoma
disease progression
prognostic factors
biomarkers
RNA sequencing
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine
Clear Cell Renal Cell Carcinoma 2021–2022
title Clear Cell Renal Cell Carcinoma 2021–2022
title_full Clear Cell Renal Cell Carcinoma 2021–2022
title_fullStr Clear Cell Renal Cell Carcinoma 2021–2022
title_full_unstemmed Clear Cell Renal Cell Carcinoma 2021–2022
title_short Clear Cell Renal Cell Carcinoma 2021–2022
title_sort clear cell renal cell carcinoma 2021 2022
topic clear cell renal cell carcinoma
prognosis
plasma
PD-1
PD-L1
renal cell carcinoma
immune checkpoint inhibitors
immune related adverse events (irAEs)
thyroid
cutaneous
biomarker
DNA methylation
epigenetics
kidney
hypoxia
tumor microenvironment
SCD-1
oleic acid
renal cancer
sunitinib
resistance
miRNA
transcriptome
pathway analysis
nivolumab
tissue slice culture
PD1
T-cells
metastatic clear cell renal cell carcinoma
first-line treatment
immunotherapy
tyrosine kinase inhibitors
combinations
single-cell RNA sequencing
immune landscape
cancer immunotherapy
intra-tumoral heterogeneity
inter-tumoral heterogeneity
inter-metastatic heterogeneity
renal cell cancer
treatment resistance
angiogenesis
adjuvant therapy
prediction model
prognostic factor
clear cell kidney cancer
radiogenomics
radiomics
machine learning
gene expression
cystic tumor
imaging
magnetic resonance
surgery
ddPCR
circulating miRNA
diagnosis
malignancy
histomorphological features
PBRM1
immunohistochemistry
architectural patterns
endothelial cells
translational
immune checkpoint inhibitor
responsiveness
molecular features
multisite tumor sampling
intratumor heterogeneity
clear-cell renal cell carcinoma
disease progression
prognostic factors
biomarkers
RNA sequencing
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine
topic_facet clear cell renal cell carcinoma
prognosis
plasma
PD-1
PD-L1
renal cell carcinoma
immune checkpoint inhibitors
immune related adverse events (irAEs)
thyroid
cutaneous
biomarker
DNA methylation
epigenetics
kidney
hypoxia
tumor microenvironment
SCD-1
oleic acid
renal cancer
sunitinib
resistance
miRNA
transcriptome
pathway analysis
nivolumab
tissue slice culture
PD1
T-cells
metastatic clear cell renal cell carcinoma
first-line treatment
immunotherapy
tyrosine kinase inhibitors
combinations
single-cell RNA sequencing
immune landscape
cancer immunotherapy
intra-tumoral heterogeneity
inter-tumoral heterogeneity
inter-metastatic heterogeneity
renal cell cancer
treatment resistance
angiogenesis
adjuvant therapy
prediction model
prognostic factor
clear cell kidney cancer
radiogenomics
radiomics
machine learning
gene expression
cystic tumor
imaging
magnetic resonance
surgery
ddPCR
circulating miRNA
diagnosis
malignancy
histomorphological features
PBRM1
immunohistochemistry
architectural patterns
endothelial cells
translational
immune checkpoint inhibitor
responsiveness
molecular features
multisite tumor sampling
intratumor heterogeneity
clear-cell renal cell carcinoma
disease progression
prognostic factors
biomarkers
RNA sequencing
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine
url ONIX_20221117_9783036555188_45